Abstract

Phytotherapy can enhance the beneficial health outcomes in the prevention of obesity and is able to improve the function of the metabolic organs, like the liver and kidneys. Since sea buckthorn (SBT) and grape extracts are known as abundant sources of polyphenol, we assumed that the extracts of these two plants might have a hypolipidemic effect and an improved metabolic function in obese rats treated with atorvastatin. One hundred and twelve white Wistar rats were divided equally into seven groups (G.I–VII) and orally treated as follows: G.I, atorvastatin 20 mg × kg·bw−1; G.II, atorvastatin 20 mg × kg·bw−1 + SBT 100 mg × kg·bw−1; G.III, atorvastatin 20 mg × kg·bw−1 + grape extract 100 mg × kg·bw−1; G.IV, grape extract 100 mg × kg·bw−1; G.V, SBT 100 mg × kg·bw−1; G.VI, high-fat diet (HFD); group VII was considered the control group. After two and six months of administration, the rats were sacrificed, and blood samples were taken for biochemical analyses. The statistical results (analysis of variance (ANOVA)) showed that a combination of SBT and grape extracts with atorvastatin significantly reduced (p ˂ 0.001) the lipid parameters. After six months, the liver and kidneys improved their functioning, showing a statistically significant change (p ˂ 0.001) in the grape and sea buckthorn groups compared to the other groups. In addition, grape extract and SBT combined with atorvastatin proved to be potent hypolipidemic agents, so associations with phytodietary supplements can be considered as a valuable means of combating hypolipidemia and decreasing risk factors.

Highlights

  • Dyslipidemia is characterized by irregular levels of lipid parameters, such as low-density lipoprotein cholesterol (LDL-c), triglycerides, high-density lipoprotein cholesterol (HDL-c), and atherogenic fractions in the bloodstream

  • The high-fat diet (HFD) group illustrated a significant rise in total cholesterol (TC) (95.9 ± 5.1), TG (245.6 ± 30.1), and LDL-c (16.2 ± 1.6) as well as a clear decline in HDL-c (7.6 ± 0.9) after six months of HFD administration

  • The results proved that plants rich in polyphenolic compounds are able to successfully support the metabolic organs’ functioning, and that the constant intake of sea buckthorn (SBT) or grape extract—alone or in combination with atorvastatin therapy—may be considered as an adjuvant in the treatment of patients suffering from metabolic-syndrome-like obesity

Read more

Summary

Introduction

Dyslipidemia is characterized by irregular levels of lipid parameters, such as low-density lipoprotein cholesterol (LDL-c), triglycerides, high-density lipoprotein cholesterol (HDL-c), and atherogenic fractions in the bloodstream. It is one of the current abnormalities and is one of the main components of the metabolic syndrome, as well as a frequent challenge that leads to morbidity and mortality [1]. Data has shown that lipid-lowering therapies can diminish the growth of coronary atherosclerosis [3] With this aim, a major goal of clinical treatment of cardiovascular disease (CVD) is risk minimization by completing healing target levels for any lipid parameter [4]; for regulating these, “statins” are involved, since they can reduce the LDL-c levels by up to 55% [5,6]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call